Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP: RVVTF )

0.0083 UNCHANGED
Streaming Delayed Price Updated: 3:05 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0083
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0083
Today's Range 0.0083 - 0.0083
52wk Range 0.0055 - 0.0360
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire

Performance

YTD
-63.11%
-63.11%
1 Month
+38.33%
+38.33%
3 Month
-23.85%
-23.85%
6 Month
-58.91%
-58.91%
1 Year
-62.27%
-62.27%

More News

Read More
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Corporate Update
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
From Revive Therapeutics Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.